On May 28, 2026 Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, reported the closing of its previously announced marketed public offering of units (the "Units") of the Company at a price to the public of CDN$0.50 per Unit (the "Offering"), for aggregate gross proceeds to the Company of approximately CDN$4.44 million, before deducting Offering expenses and excluding any proceeds the Company may receive from the exercise of the underlying warrants. Pursuant to the Offering, the Company issued a total of 8,880,000 Units. Each Unit is comprised of one common share and one-half of one common share purchase warrant of the Company (each whole common share purchase warrant, a "Warrant"). Each Warrant entitles the holder thereof to acquire one common share of the Company (a "Warrant Share") at an exercise price of $0.65 per Warrant Share until the date that is three years following the initial closing date of the Offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Offering was made pursuant to an agency agreement (the "Agency Agreement") entered into between Bloom Burton Securities Inc., as sole agent (the "Agent"), and the Company dated May 21, 2026. An aggregate of 450,100 compensation warrants of the Company (each, a "Broker Warrant") were issued by the Company in connection with the Agency Agreement, each Broker Warrant entitling the holder to acquire one common share of the Company at an exercise price of $0.50 per share until the date that is two years following the initial closing date of the Offering.

The Offering was made pursuant to a prospectus supplement (the "Prospectus Supplement") dated May 21, 2026 to the Company’s existing short form base shelf prospectus dated June 4, 2025 (the "Base Shelf Prospectus") filed in the Provinces of British Columbia, Alberta and Ontario. The Units may also be offered in certain other jurisdictions outside of Canada, provided that a placement therein does not give rise to any prospectus, registration or continuous disclosure obligations on the part of the Company.

The Base Shelf Prospectus, the Agency Agreement and the Prospectus Supplement are available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

The securities of the Company described above have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), or any U.S. state securities laws and may not be offered or sold to, or for the account or benefit of, persons in the "United States" or "U.S. Persons" (as such terms are defined in Regulation S under the 1933 Act) except pursuant to an effective registration statement under the 1933 Act and applicable U.S. state securities laws or an available exemption from the registration requirements of the 1933 Act and applicable U.S. state securities laws.

In addition to the above Offering and as announced previously, the Company has entered into a separate structured financing of CDN$8.0 million with Sorbie Bornholm LP and Sorbie Investments LLP ("Sorbie").

This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Medicenna Therapeutics, MAY 28, 2026, View Source [SID1234666148])

On May 28, 2026 Massive Bio, a global leader in AI-enabled oncology trial access and precision oncology navigation, reported that it will unveil the next phase of Reticulum Nexus, its trusted multi-agent oncology intelligence ecosystem, during the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Reticulum Nexus is designed to address one of oncology’s most persistent failures: the gap between the rapid pace of cancer innovation and the ability of patients, physicians, trial sites, and sponsors to coordinate action in real time. The platform connects patient engagement, medical record ingestion, eligibility interpretation, clinical trial pre-screening, physician referral orchestration, biomarker intelligence, site activation, patient navigation, and longitudinal follow-up into a single AI-enabled operating layer.

"Cancer patients are not lost because science is absent. They are lost because the system around them is fragmented," said Selin Kurnaz, PhD, Co-Founder and CEO of Massive Bio. "Reticulum Nexus was built to make oncology access coordinated, measurable, trusted, and fast. We are moving from point solutions to infrastructure."

The ASCO (Free ASCO Whitepaper) announcement builds on several recent Massive Bio milestones: the company’s collaboration with OpenAI to transform complex trial criteria into structured, machine-readable parameters for AI-enabled pre-screening; its collaboration with the American Cancer Society’s ACS ACTS program to expand equitable clinical trial access nationally; its DiMe Seal and CMS Medicare App Library listing; and the publication of peer-reviewed prospective evidence demonstrating AI-driven trial matching at scale.

From Trial Matching to Oncology Orchestration

For years, cancer trial access has been treated as a search problem: find a patient, find a protocol, compare eligibility, and generate a match. But in real-world oncology, matching is only the beginning. Patients need records collected, eligibility clarified, biomarkers interpreted, physicians engaged, referrals routed, sites activated, social barriers addressed, and follow-up maintained.

Reticulum Nexus is designed to orchestrate those steps through coordinated AI agents and human-in-the-loop workflows. The ecosystem brings together Patient Connect, the patient-facing digital front door for record upload, trial matching, and care coordination; TrialRelay, the physician-facing referral orchestration platform powered by the TrialRouter AI agent; NexusPulse, the real-time AI signal engine that turns consented real-world data into prioritized next-best actions; DrArturo AI, the clinician-facing oncology intelligence agent; Phoebe AI, the patient-facing navigation intelligence agent; and Sentinel Agents, a family of monitoring agents designed to detect critical clinical, operational, equity, safety, and biomarker signals earlier in the patient journey.

"Reticulum Nexus is not a chatbot and it is not a dashboard," said Arturo Loaiza-Bonilla, MD, MSEd, FACP, Co-Founder and Chief Medical AI Officer of Massive Bio. "It is a multi-agent oncology operating system. It understands context, detects urgency, routes action, supports clinicians, engages patients, and keeps the workflow moving until the loop is closed."

Built on Trust, Evidence, and National Reach

The next phase of Reticulum Nexus is being launched at a time when oncology AI is moving from experimentation to operational deployment. Massive Bio’s April 2026 collaboration with OpenAI is focused on AI-powered protocol parameterization and pre-screening, allowing complex clinical trial criteria from sponsors and public registries to be transformed into structured, machine-readable parameters.

The company’s platform has earned the DiMe Seal and is listed in the CMS Medicare App Library, a trusted centralized directory where Medicare beneficiaries can discover vetted digital health options that have undergone review for security, privacy, clinical evidence, usability, and equity. The Medicare.gov App Library lists Massive Bio Patient Navigator as helping cancer patients find and access matched clinical trials and personalized care options based on diagnosis, genomic profile, and treatment history.

Through the American Cancer Society’s ACS ACTS program, ACS is working with Massive Bio for AI-driven clinical trial matching services to bring patients tailored options and support resources, including education, cancer information specialist support, transportation, lodging, and other needs-based assistance.

Massive Bio’s recent peer-reviewed prospective study reported that its neuro-symbolic, multi-agent AI platform matched cancer patients to clinical trials four times faster than conventional methods, across 3,804 patients, more than 157,000 clinical document pages, and more than 17,000 oncologist-confirmed trial matches.

"Trust is the multiplier," said Selin Kurnaz. "AI in oncology cannot scale on novelty alone. It must be evidence-based, privacy-aware, interoperable, auditable, and grounded in real patient workflows. That is why Reticulum Nexus is being built not just as technology, but as infrastructure."

ASCO Demonstration: The Closed-Loop Oncology Journey

At ASCO (Free ASCO Whitepaper) 2026, Massive Bio will demonstrate how Reticulum Nexus can coordinate a patient journey from first engagement to trial activation. A patient may enter through Patient Connect, provide consent, and upload records. DrArturo AI can help structure the clinical context. OpenAI-enabled parameterization can support protocol interpretation and pre-screening. NexusPulse can detect urgency, trial opportunity, biomarker gaps, or access friction. Sentinel Agents can monitor clinical, referral, safety, and equity signals. TrialRelay can route physician-to-physician handoffs. Phoebe AI can support patient education, navigation, and follow-up. ACS ACTS resources can help address support needs.

The result is a coordinated, human-in-the-loop infrastructure designed to help patients move from possibility to action.

"Massive Bio is turning clinical trial access from a search problem into a real-time orchestration problem," said Dr. Loaiza-Bonilla. "The science is there. The patients are there. What has been missing is the operating system that connects them. That is Reticulum Nexus."

(Press release, Massive Bio, MAY 28, 2026, View Source [SID1234666147])

On May 28, 2026 Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported that the Company’s senior management team will participate at the 2026 Jefferies Global Healthcare Conference in a fireside chat on Thursday, June 4, 2026 at 8:10 a.m. ET in New York, NY.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investors & Media section of the Company’s website, View Source, and will be available for replay following the event.

(Press release, Karyopharm, MAY 28, 2026, View Source [SID1234666146])

On May 28, 2026 INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, reported that it will participate in the following scientific and investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Global Healthcare Conference (New York)
Date: Thursday, June 4
Time: 8:45 AM ET
Format: Fireside Chat
Webcast: https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/adRiTkvKf4AnDsZYyXatz8

World Orphan Drug Congress (Boston)
Poster Presentation: Rare Disease Protein Replacement Therapeutics: The Transformational Potential of Next-Gen DNA Medicine Date: Thursday, June 11
Time: 12:00 – 12:10 PM ET

A replay of the investor event will be available for 90 days at the link above. Members of INOVIO’s management team will also be conducting one-on-one meetings with investors during the investor conference.

(Press release, Inovio, MAY 28, 2026, View Source [SID1234666145])

On May 28, 2026 Enterome SA, a clinical-stage company pioneering OncoMimics, a new class of off-the-shelf, multi-targeted in vivo immune therapies, reported that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to EO2463 for the treatment of patients with indolent non-Hodgkin lymphoma (iNHL) in the low-tumor-burden, "watch-and-wait" setting. The U.S. FDA Fast Track designation was also granted in October 2025 to EO2463 for follicular lymphoma in the watch-and-wait setting, further underscoring its potential and the unmet medical need.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The US FDA orphan drug designation (ODD) confers several substantial financial, regulatory, and strategic advantages to sponsors developing therapies for rare diseases affecting fewer than 200,000 people in the United States. For example, upon marketing approval, orphan-designated products receive 7 years of market exclusivity in the US.

"Receiving FDA Orphan Drug Designation is an important regulatory milestone for EO2463 and re-affirms our strong commercial potential. Today, the only option for non-symptomatic low tumor burden "watch-and-wait" iNHL patients is to go without treatment and be observed until the cancer progresses. We believe this places undue stress on patients and their families and is unacceptable; it is gratifying to see the U.S. regulatory agency recognizes that ‘watch-and-wait’ patients deserve a real treatment option like EO2463," said Pierre Belichard, Chief Executive Officer of Enterome. "Together with the Fast Track designation granted late last year, FDA’s ODD further facilitates and validates our efforts to advance EO2463 toward registrational development in the watch-and-wait population. We are actively engaging with potential partners and investors to find the best path forward to rapidly advance EO2463 development in this indication."

Data from SIDNEY, which have been reported at multiple peer-reviewed medical conferences, demonstrate that EO2463 is particularly well suited for watch-and-wait iNHL patients because it has been well tolerated in clinical testing and has shown potentially disease modifying monotherapy activity in patients who generally are not eligible to receive anti-lymphoma treatment under current practice until their disease progresses. Data also suggest that EO2463 may be highly complementary when used in combination with marketed cancer therapeutics, offering potential additional disease modifying effects.

In the low-tumor-burden watch-and-wait population of SIDNEY Cohort 2, Enterome reported that EO2463 monotherapy produced a 52.6% objective response rate in 19 evaluable patients with follicular lymphoma and a 47.6% objective response rate in the overall group of 21 evaluable patients with follicular lymphoma or marginal zone lymphoma, including 14.3% complete responses and 33.3% partial responses.

Separately, Enterome reported that EO2463 rapidly induced extensive in vivo expansion of B-cell-target-specific CD8 T cells and established a correlation between EO2463-induced and B-cell-target-specific CD8 T-cell expansion and Lugano objective response, suggesting this immune readout may serve as a predictive biomarker in indolent NHL, something that would further serve to alleviate anxiety in watch-and-wait patients and help physicians decide which patients to monitor more closely.

And in addition to the impact in watch-and-wait patients, Enterome reported that EO2463 combined with lenalidomide and rituximab achieved a 60% complete response rate in 20 patients with relapsed/refractory follicular and marginal zone lymphoma, was well tolerated, and showed CD8 T-cell expansion correlating with the probability of complete remission, findings the company described as complementary to the monotherapy signal seen in watch-and-wait patients and show that EO2463 may also be complementary when used in combination with rituximab and other cancer therapeutics.

SIDNEY is an ongoing open-label Phase 1/2 study evaluating the safety, tolerability, immunogenicity and preliminary efficacy of EO2463 as monotherapy and in combination regimens in up to 55 patients with follicular lymphoma and marginal zone lymphoma. The trial includes a dedicated watch-and-wait monotherapy cohort, a first-line low-tumor-burden combination cohort with rituximab, and relapsed/refractory cohorts treated with EO2463 plus lenalidomide and rituximab.

EO2463 is an off-the-shelf OncoMimics active immunotherapy composed of four synthetic microbial-derived peptides designed to mimic the B-cell lineage markers CD20, CD22, CD37 and CD268 (BAFF receptor), plus the helper peptide UCP2. According to Enterome, this multi-target approach is intended to expand pre-existing memory CD8 T cells, selectively target malignant B cells, broaden target coverage and reduce the risk of antigen escape.

OncoMimics consist of bacteria-derived peptide antigens that closely mimic tumor-associated antigens (TAAs) of solid tumors, or cell linage markers (e.g. as observed in B cell lymphomas). These antigens induce a fast and potent in vivo expansion of cytotoxic memory CD8 T-cells, primed by gut bacteria, and cross-reactive with TAAs/B cell markers. Because the peptides are "non-self", OncoMimics avoid the self-tolerance that limits many cancer immunotherapies to enable rapid, potent, and durable responses to tumors. The synthetically produced peptides are designed in silico, mining Enterome’s proprietary database of 23 million commensal bacteria genes. Each product combines multiple high-affinity peptides to broaden target coverage and mitigate tumor heterogeneity.

(Press release, Enterome, MAY 28, 2026, View Source [SID1234666144])